PDCD1 and cancer: Programmed cell death-1 (PD-1) inhibitors as a type of ICIs are designed to boost T-cell activation and levels of proinflammatory cytokines along with concentrations of autoimmune antibodies against cancer by blocking PD-1 protein expression (2).